Ozone therapy is generally considered safe when administered properly, but there are specific medical conditions that make it dangerous or potentially life-threatening. The most critical is glucose-6-phosphate dehydrogenase (G6PD) deficiency, an absolute contraindication that can cause severe hemolytic anemia if ozone contacts the patient’s blood. Beyond G6PD deficiency, several relative contraindications require careful evaluation before proceeding. This guide covers every major contraindication, explains why each one matters, and outlines the pre-treatment screening that responsible practitioners should perform.
Understanding who should not receive ozone therapy is just as important as understanding who might benefit from it.
Key Takeaways
- G6PD deficiency is the only absolute contraindication for systemic ozone therapy (MAH, 10-Pass, rectal insufflation). Ozone can trigger fatal hemolytic anemia in G6PD-deficient patients1
- Relative contraindications include uncontrolled hyperthyroidism, pregnancy, active hemorrhage, recent MI, and organ transplant with immunosuppression
- All patients should be screened for G6PD deficiency before any blood-contact ozone therapy2
- Certain medications (ACE inhibitors, anticoagulants) require dose adjustment or monitoring during ozone therapy
- Topical and local ozone applications (ozonated water, ozonated oil, limb bagging) have fewer contraindications than systemic treatments
- Practitioners who do not screen for G6PD deficiency before systemic ozone therapy are not following established safety protocols
Absolute Contraindication: G6PD Deficiency
Glucose-6-phosphate dehydrogenase (G6PD) deficiency is an inherited enzyme disorder that affects approximately 400 million people worldwide. It is most common in people of African, Mediterranean, Middle Eastern, and Southeast Asian descent, with prevalence rates of 10 to 25% in some populations.3
G6PD is essential for protecting red blood cells from oxidative damage. The enzyme maintains levels of reduced glutathione, which neutralizes reactive oxygen species that would otherwise destroy the red blood cell membrane. Without adequate G6PD, red blood cells are extremely fragile and vulnerable to oxidative stress.
Ozone therapy works precisely by introducing a controlled oxidative stress. In a patient with normal G6PD levels, this stress activates protective antioxidant pathways. In a G6PD-deficient patient, the same oxidative stress can cause massive hemolysis: the rapid destruction of red blood cells.
The consequences of ozone therapy in G6PD-deficient patients can include:
- Acute hemolytic anemia (rapid red blood cell destruction)
- Hemoglobinuria (hemoglobin in urine, dark or cola-colored urine)
- Jaundice
- Kidney failure (from hemoglobin clogging renal tubules)
- Death in severe cases
“G6PD deficiency is the only absolute contraindication for ozone therapy involving blood contact. Screening is mandatory before Major Autohemotherapy, 10-Pass, or any procedure where ozone contacts the patient’s blood.”
Based on Bocci, Ozone: A New Medical Drug, 2011
This is not a theoretical risk. Published case reports document hemolytic crises in G6PD-deficient patients exposed to oxidative stressors. Any practitioner who performs systemic ozone therapy (MAH, 10-Pass, high-dose ozone) without first testing for G6PD deficiency is not following established safety protocols.
G6PD Screening
G6PD testing is a simple blood test available at any standard laboratory. It costs $20 to $50 and results are typically available within 1 to 3 days. The test measures G6PD enzyme activity in red blood cells.
| G6PD Status | Ozone Therapy |
|---|---|
| Normal activity | All forms of ozone therapy may proceed |
| Partial deficiency | Systemic ozone therapy is contraindicated; topical applications may be considered with caution |
| Severe deficiency | All systemic ozone therapy is absolutely contraindicated |
Important note: G6PD levels can be falsely normal during or immediately after a hemolytic episode (because the deficient cells have already been destroyed). Testing should be done when the patient is in a stable, non-hemolytic state.
Relative Contraindications
Relative contraindications mean the treatment is not automatically ruled out but requires careful risk-benefit analysis, dose adjustment, or postponement until the condition is controlled.
Uncontrolled Hyperthyroidism
Hyperthyroidism increases the body’s metabolic rate and oxygen consumption. Ozone therapy, particularly systemic forms, further increases metabolic activity and oxygen utilization. In patients with uncontrolled hyperthyroidism, this combination can precipitate thyroid storm, a life-threatening condition characterized by extreme tachycardia, hyperthermia, and organ failure.1
Patients with controlled hyperthyroidism (on appropriate medication with normal thyroid function tests) can typically proceed with ozone therapy after clearance from their endocrinologist.
Pregnancy
Ozone therapy has not been studied in pregnant women, and no safety data exists for fetal exposure. Given the oxidative mechanism of action and the theoretical risk to fetal development, systemic ozone therapy is contraindicated during pregnancy as a precautionary measure.2
This is a precautionary contraindication based on the absence of safety data rather than documented harm. The standard medical principle applies: when safety data does not exist for a vulnerable population, the treatment is avoided.
Active Hemorrhage
Ozone therapy, particularly MAH and high-dose protocols, can affect coagulation parameters. In patients with active bleeding from any cause (gastrointestinal hemorrhage, trauma, post-surgical bleeding), ozone therapy should be postponed until the bleeding is controlled and the patient is hemodynamically stable.
Additionally, blood draw required for MAH could worsen anemia in actively bleeding patients.
Recent Myocardial Infarction
In the immediate post-MI period (typically first 3 to 6 months), the cardiovascular system is unstable and vulnerable to additional stressors. While ozone therapy is not inherently dangerous to the heart, the physiological stress of treatment (including blood volume shifts during MAH) and the risk of arrhythmia in a recently infarcted heart make postponement advisable.
Patients with stable coronary artery disease or remote history of MI (more than 6 months, with good cardiac function) can typically proceed with appropriate monitoring.
Organ Transplant with Immunosuppression
Ozone therapy has immunomodulatory effects. At low doses, it stimulates immune function. For organ transplant recipients, whose survival depends on immune suppression to prevent rejection, any immune stimulation is potentially dangerous.
Ozone’s activation of T cells, natural killer cells, and cytokine production could theoretically trigger acute rejection episodes. Until studies specifically evaluate ozone therapy in transplant patients, it should be avoided in this population.1
Severe Anemia
Patients with hemoglobin levels below 7 g/dL should not undergo MAH or any ozone therapy that involves blood withdrawal. The volume of blood removed (100 to 200 mL for standard MAH) could worsen anemia and compromise oxygen delivery. Additionally, severely anemic patients have reduced antioxidant capacity, increasing the risk of oxidative damage.
Seizure Disorders (Uncontrolled)
While ozone therapy does not directly cause seizures, the oxygen component of some protocols may lower seizure threshold. Patients with well-controlled epilepsy on stable medication can typically proceed with caution. Patients with uncontrolled seizures should avoid treatment until their condition is stabilized.
Medication Interactions
Certain medications require consideration when planning ozone therapy:
| Medication | Concern | Action |
|---|---|---|
| Anticoagulants (warfarin, heparin) | Ozone may affect coagulation; combined effect could increase bleeding risk | Monitor INR closely; dose adjustment may be needed |
| ACE inhibitors | Some practitioners report enhanced hypotensive effect during MAH | Monitor blood pressure during treatment |
| Immunosuppressants | Ozone’s immunomodulatory effects may counteract immunosuppression | Avoid systemic ozone or consult prescribing physician |
| Copper or iron supplements | Free copper and iron catalyze harmful Fenton reactions with ozone-generated ROS | Withhold on treatment days |
| High-dose antioxidants (IV vitamin C) | May neutralize ozone’s therapeutic oxidative effect | Separate by at least 2 hours; some practitioners advise separate days |
What Proper Pre-Treatment Screening Looks Like
A responsible ozone therapy provider should perform the following before initiating systemic treatment:
- G6PD test (mandatory for any blood-contact ozone therapy)
- Complete blood count (to rule out severe anemia and assess baseline)
- Thyroid function panel (TSH, free T3, free T4 to screen for uncontrolled hyperthyroidism)
- Detailed medical history covering cardiac events, bleeding disorders, pregnancy status, seizure history, and current medications
- Organ transplant and immunosuppression status
If your provider does not ask about G6PD status or offer testing before MAH, 10-Pass, or other systemic ozone protocols, that is a red flag. This is the single most important safety check in ozone therapy, and skipping it is inexcusable.
Local vs. Systemic: Different Risk Profiles
Not all forms of ozone therapy carry the same contraindication profile. Topical and local applications have significantly fewer restrictions:
| Ozone Modality | G6PD Risk | Other Contraindications |
|---|---|---|
| MAH / 10-Pass | High (blood contact) | All listed above apply |
| Rectal insufflation | Moderate (systemic absorption) | Most systemic contraindications apply; lower risk overall |
| Ozone injection (joint/disc) | Low (local effect) | Local infection, anticoagulation concerns |
| Limb bagging / topical | Minimal | Open wounds (may sting); avoid inhalation of ozone gas |
| Ozonated water / oil | None | Allergy to base oil (for ozonated oil); generally very safe |
The Bottom Line
Ozone therapy has a favorable safety profile when administered to appropriately screened patients by qualified practitioners. The key is screening. G6PD testing before any blood-contact ozone therapy is non-negotiable. Patients with uncontrolled hyperthyroidism, active hemorrhage, recent heart attacks, pregnancy, or immunosuppression from organ transplant should either avoid systemic ozone therapy or proceed only after careful evaluation.
When evaluating an ozone therapy provider, the quality of their pre-treatment screening tells you a lot about the quality of their practice. A provider who does not test for G6PD deficiency is cutting a corner that could cost a patient their life.
Related reading: Ozone Therapy Side Effects: What to Expect
References
- Bocci V. Ozone: A New Medical Drug. 2nd ed. Springer; 2011. doi:10.1007/978-90-481-9234-2
- Smith NL, Wilson AL, Gandhi J, et al. Ozone therapy: an overview of pharmacodynamics, current research, and clinical utility. Med Gas Res. 2017;7(3):212-219. doi:10.4103/2045-9912.215752
- Cappellini MD, Fiorelli G. Glucose-6-phosphate dehydrogenase deficiency. Lancet. 2008;371(9606):64-74. doi:10.1016/S0140-6736(08)60073-2
Medical Disclaimer
The content on BaricBoost.com is for informational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.
Author
Seph Fontane Pennock is the founder of BaricBoost.com and Regenerated.com, a clinic directory for regenerative medicine serving 10,000+ providers across the United States. He previously built and sold PositivePsychology.com, which grew to 19 million users and became the largest evidence-based positive psychology resource on the web. Seph brings direct experience as an HBOT patient, having completed protocols at clinics across three continents while navigating mold illness, systemic inflammation, and autoimmune conditions. His treatment journey includes hyperbaric oxygen therapy, peptide protocols, NAD+ therapy, and consultations with specialists from Dubai to Cape Town to Mexico. This combination of entrepreneurial track record and lived patient experience shapes everything published on BaricBoost.com. Every article is grounded in peer-reviewed research, informed by real clinical encounters, and written for patients making high-stakes treatment decisions. Seph's focus is on bringing transparency, scientific rigor, and practical guidance to the hyperbaric oxygen therapy space.
